<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Chronic kidney disease-associated pruritus</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Chronic kidney disease-associated pruritus</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Chronic kidney disease-associated pruritus</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Berns, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Steve J Schwab, MD, FACP, FASN</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric N Taylor, MD, MSc, FASN</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 21, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H22781493"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Pruritus (itch) is a common symptom among patients on maintenance dialysis that in many cases substantially impairs quality of life [<a href="#rid1">1-3</a>]. Less frequently, pruritus also occurs in patients with nondialysis chronic kidney disease (CKD). The pathophysiology is incompletely understood, and it is often difficult to eradicate although symptoms can usually be mitigated.</p><p>Although often referred to as "uremic pruritus," itch in this setting often occurs in adequately dialyzed patients or, in patients not on dialysis, in the absence of other symptoms associated with uremia. Thus, the preferred term is chronic kidney disease–associated pruritus (CKD-aP). CKD-aP is discussed in this topic review; a general discussion of pruritus is presented separately. (See  <a class="medical medical_review" href="/z/d/html/5576.html" rel="external">"Pruritus: Therapies for localized pruritus"</a>.)</p><p class="headingAnchor" id="H98332764"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H2986342587"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>The reported prevalence of CKD-aP in adult patients with end-stage kidney disease has decreased with more effective dialysis [<a href="#rid4">4</a>]. Whereas the reported prevalence between 1980 and 1993 was 50 to 90 percent [<a href="#rid5">5-7</a>], subsequent surveys noted a lower rate (22 to 57 percent) [<a href="#rid8">8-11</a>]. In a report from a prospective cohort study (the Dialysis Outcomes and Practice Patterns Study [DOPPS]) that included more than 20,000 patients on hemodialysis, the prevalence of at least moderate pruritus was 37 percent, a rate that was relatively constant from 2009 to 2018 [<a href="#rid12">12</a>]. Seven percent of patients in this study reported that they were extremely bothered by pruritus.</p><p>Pruritus is underreported by patients and underappreciated by medical staff. For example, in reports of DOPPS participants who had severe pruritus, 18 percent received no treatment for pruritus, and 17 percent did not even report their itch symptoms to health care staff [<a href="#rid10">10,13</a>]. Over two-thirds of medical directors underestimated the prevalence of pruritus in their units [<a href="#rid10">10,13</a>].</p><p>The prevalence has not been as well studied in patients on peritoneal dialysis and in children. Historically, small series suggested that the prevalence is lower in children (approximately 9 percent) and similar between patients on hemodialysis and those on peritoneal dialysis [<a href="#rid14">14-16</a>]. However, two studies from Korea and Taiwan compared the prevalence of pruritus between patients on hemodialysis and those on peritoneal dialysis and showed conflicting results. The Korean study showed a higher rate of pruritus in patients on peritoneal dialysis compared with those on hemodialysis (68.2 versus 48.3 percent, respectively), whereas the Taiwanese cohort showed no significant difference between patients on hemodialysis and those on peritoneal dialysis [<a href="#rid17">17,18</a>].</p><p>CKD-aP in patients with nondialysis CKD is less common. In a report from a prospective cohort study that included over 5600 patients with stages 3, 4, and 5 nondialysis CKD, the prevalence of at least moderate pruritus was 24 percent, and of extreme pruritus was less than five percent [<a href="#rid19">19</a>]. The prevalence and severity of pruritus increased with CKD stage.</p><p class="headingAnchor" id="H3097732692"><span class="h2">Risk factors and associations</span><span class="headingEndMark"> — </span>No single cause underlying CKD-aP has been identified. Multiple factors have been associated in observational studies, and supportive therapies that are used to treat CKD-aP have targeted such factors. (See <a class="local">'Management'</a> below.)</p><p>The following factors have been identified in multiple studies:</p><p class="bulletIndent1"><span class="glyph">●</span>Inadequate dialysis [<a href="#rid9">9,20,21</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Hyperparathyroidism [<a href="#rid22">22-24</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated serum calcium and/or phosphorus concentrations [<a href="#rid9">9,24-26</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Xerosis (dry skin caused by sweat gland atrophy) [<a href="#rid27">27,28</a>]</p><p class="bulletIndent1"><span class="glyph">●</span>Elevated serum magnesium and aluminum concentrations [<a href="#rid29">29-31</a>]</p><p></p><p>However, not all studies observed associations between elevated levels of parathyroid hormone or phosphorus and pruritus [<a href="#rid13">13</a>]. Other data suggest the following potential risk factors: anemia, male sex, hypervitaminosis-A, increased beta-2 microglobulin levels, serotype human leukocyte antigen (HLA)-B35, and comorbidities including congestive heart failure, neurologic disease, and ascites [<a href="#rid10">10,25,32-34</a>].</p><p>Risk appears to be independent of ethnicity, type of dialysis, and underlying kidney disease [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H14965810"><span class="h1">PATHOPHYSIOLOGY</span><span class="headingEndMark"> — </span>The pathophysiology of CKD-aP is poorly understood. Hypotheses implicating immunologic and opioidergic systems have been proposed [<a href="#rid35">35</a>].</p><p class="headingAnchor" id="H1729208"><span class="h2">Immunohypothesis</span><span class="headingEndMark"> — </span>The immunohypothesis proposes that CKD-aP is the result of systemic inflammation rather than a local skin disorder [<a href="#rid36">36,37</a>]. Immunomodulating therapies such as ultraviolet B (UVB) phototherapy, <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a>, and calcineurin inhibitors have been shown to decrease CKD-aP in some studies [<a href="#rid38">38-40</a>].</p><p>A direct role for proinflammatory T cells and cytokines is suggested by studies that showed higher levels of proinflammatory T helper-1 (TH1) cells, C-reactive protein, interleukin 6, and interleukin 2 among patients on hemodialysis with versus those without pruritus [<a href="#rid37">37,41</a>]. Other markers of inflammation including increased white blood cell count, low albumin, and high ferritin have also been associated with uremic pruritus in various studies [<a href="#rid10">10,42</a>].</p><p class="headingAnchor" id="H1729277"><span class="h2">Opioid hypothesis</span><span class="headingEndMark"> — </span>The opioid hypothesis proposes that imbalances in the expression of mu and kappa opioid receptors cause pruritus [<a href="#rid43">43,44</a>]. Thus, pruritus is increased by mu-receptor activation and kappa-receptor blockade and decreased by kappa-receptor activation and mu-receptor blockade [<a href="#rid45">45</a>]. This hypothesis is supported by the observation that the ratio of the mu-receptor agonist (beta-endorphin) to the kappa-receptor agonist (dynorphin-A) is increased in patients on hemodialysis compared with healthy controls, and this ratio increased with severity of pruritus [<a href="#rid46">46</a>].</p><p class="headingAnchor" id="H22425983"><span class="h2">Other contributing factors</span><span class="headingEndMark"> — </span>Mast cell release of histamine and other pruritogens and xerosis may all contribute to the pathogenesis of CKD-aP [<a href="#rid43">43,47-49</a>].</p><p class="headingAnchor" id="H22781508"><span class="h1">CLINICAL CHARACTERISTICS</span><span class="headingEndMark"> — </span>CKD-aP most commonly affects the back but may also involve the arms, head, and abdomen [<a href="#rid10">10,50</a>]. Generalized pruritus is also noted in a significant number of patients. Some patients also experience pruritus for only a few minutes each day, whereas others have it nearly continuously [<a href="#rid51">51</a>].</p><p>Other characteristics include:</p><p class="bulletIndent1"><span class="glyph">●</span>Symptoms tend to be worse at night, resulting in sleep disruption [<a href="#rid8">8-10,12,50,52,53</a>]. The disruption of sleep is much worse in those with more severe pruritus, possibly resulting in marked fatigue and depression [<a href="#rid10">10,12,13</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients often report increased pruritus with heat (especially with excessive perspiration) and stress and decreased pruritus with physical activity, cooler temperatures, and with either hot or cold showers [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Some patients report exacerbation of pruritus during hemodialysis sessions, whereas pruritus appears to lessen during hemodialysis among others [<a href="#rid26">26,50</a>].</p><p></p><p>Physical findings are limited unless there are superimposed dermatologic conditions from repetitive scratching such as excoriations, lichen simplex, pruritus nodularis, keratotic papules, and follicular hyperkeratosis [<a href="#rid6">6</a>]. Xerosis (dry skin), which is present in most patients with uremic pruritus, may not be apparent unless the skin is inspected closely, when scaling and epidermal cracking may be visible [<a href="#rid54">54</a>].</p><p>Laboratory features may include serum blood urea nitrogen (BUN), parathyroid hormone (PTH), phosphate, calcium, and magnesium levels that are markedly elevated compared with patients without pruritus. Among 1773 adult patients on hemodialysis who were stratified based upon the severity of pruritus, those with severe pruritus were more likely to have BUN &gt;81 mg/dL (odds ratio [OR] 1.4), calcium &gt;9.5 mg/dL (OR 1.4), or phosphate 6.6 mg/dL (OR 1.7) and less likely to have a PTH &lt;200 pg/mL (OR 0.6) [<a href="#rid9">9</a>].</p><p class="headingAnchor" id="H22781515"><span class="h1">DIAGNOSIS</span></p><p class="headingAnchor" id="H3695937072"><span class="h2">Making the diagnosis</span><span class="headingEndMark"> — </span>Our approach to diagnosing CKD-aP is based on the degree of kidney dysfunction:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with stage 5 CKD (including dialysis)</strong> – Since it is extremely common, we assume that pruritus presenting in patients with stage 5 CKD (whether on dialysis or not) is due to CKD-aP unless there is unequivocal and compelling evidence of another cause (eg, primary skin lesions including inflamed papules, patches, or plaques). Characteristics suggestive of uremic pruritus include onset coincident with starting dialysis, persistence of symptoms, or markedly elevated calcium/phosphate, parathyroid hormone (PTH), and/or blood urea nitrogen (BUN) levels [<a href="#rid53">53</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients without stage 5 CKD </strong>–<strong> </strong>Because the prevalence of CKD-aP is less common in patients without stage 5 CKD, we diagnose CKD-aP in such patients only after evaluating and excluding other common etiologies of pruritus that occur in the general population. (See  <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation", section on 'Evaluation'</a>.)</p><p></p><p class="headingAnchor" id="H30440440"><span class="h2">Differential diagnosis</span><span class="headingEndMark"> — </span>A significant number of diseases can cause pruritus in patients with and without kidney disease. In general, alternatives to a diagnosis of CKD-aP should be considered among patients who have persistent pruritus that is refractory to common treatments such as topical emollients, topical analgesic agents, and oral antihistamines or gabapentinoids (ie, <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>). This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation"</a>.)</p><p>It is particularly important that the clinician consider the possibility of lymphoma, cholestasis (due to primary biliary cholangitis or viral hepatitis, for example), and hypersensitivity reactions as the cause of pruritus. (See  <a class="medical medical_review" href="/z/d/html/4694.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of peripheral T cell lymphoma, not otherwise specified", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/z/d/html/3607.html" rel="external">"Pruritus associated with cholestasis"</a> and  <a class="medical medical_review" href="/z/d/html/16589.html" rel="external">"Pruritus: Etiology and patient evaluation", section on 'Dermatologic disorders'</a> and  <a class="medical medical_review" href="/z/d/html/3621.html" rel="external">"Clinical manifestations, diagnosis, and prognosis of primary biliary cholangitis", section on 'Signs and symptoms'</a> and  <a class="medical medical_review" href="/z/d/html/4688.html" rel="external">"Clinical presentation and diagnosis of classic Hodgkin lymphoma in adults", section on 'Pruritus'</a>.)</p><p class="headingAnchor" id="H22781529"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>Treatment involves a stepwise approach that depends upon the severity of symptoms and the response to sequential therapies  (<a class="graphic graphic_algorithm graphicRef142585" href="/z/d/graphic/142585.html" rel="external">algorithm 1</a>). High-quality evidence on which to base recommendations for the treatment of CKD-aP is limited. Most recommendations are based on anecdotal reports and small, uncontrolled clinical trials. Further complicating the interpretation of the studies that address management include the use of different scoring systems for the intensity of pruritus and a lack of head-to-head comparisons between different agents. In addition, many agents that have been studied may not be commercially available. Another complicating factor in interpreting the literature regarding therapies for CKD-aP is the impressive placebo effect noted in many studies [<a href="#rid55">55-57</a>]. Finally, most studies examined patients on hemodialysis; data about treatment for patients on peritoneal dialysis and those with nondialysis CKD are sparse.</p><p class="headingAnchor" id="H655794683"><span class="h2">General measures in all patients</span><span class="headingEndMark"> — </span>General measures for all patients with CKD-aP include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Optimal dialysis for patients with end-stage kidney disease since underdialysis is commonly associated with pruritus (see  <a class="medical medical_review" href="/z/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis"</a> and <a class="local">'Optimize dialysis'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Optimal treatment of hyperparathyroidism and hyperphosphatemia (see <a class="local">'Parathyroid, phosphate, and calcium'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The regular use of emollients, particularly in patients with dry skin (see <a class="local">'Skin emollients'</a> below)</p><p></p><p class="headingAnchor" id="H449976"><span class="h3">Optimize dialysis</span><span class="headingEndMark"> — </span>For patients on dialysis, optimizing the dialysis dose and/or hemodialysis membrane may decrease pruritus. For patients with nondialysis CKD, we generally do not initiate chronic dialysis solely to treat pruritus; most patients with nondialysis CKD and pruritus can be treated medically, and the established risks associated with long-term dialysis typically outweigh the possible benefit of reduced itch. (See  <a class="medical medical_review" href="/z/d/html/1866.html" rel="external">"Indications for initiation of dialysis in chronic kidney disease"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dialysis dose</strong> – For patients on dialysis with Kt/V values that are less than generally accepted Kt/V targets for hemodialysis and peritoneal dialysis, we increase the dose of dialysis to meet those targets. We do this because of overall benefit conferred as well as for the potential beneficial effect on pruritus. (See  <a class="medical medical_review" href="/z/d/html/1836.html" rel="external">"Prescribing and assessing adequate hemodialysis"</a> and  <a class="medical medical_review" href="/z/d/html/1968.html" rel="external">"Prescribing peritoneal dialysis"</a>.)</p><p></p><p class="bulletIndent1">Increasing the dose of dialysis may improve pruritus [<a href="#rid20">20,21,58</a>]. A 12-month prospective study from 1995 included 59 patients on hemodialysis without significant disorders of bone metabolism who were stratified according to the degree of pruritus observed over three months [<a href="#rid20">20</a>]. In the first phase of the study, during which the dialysis dose was not changed, dialysis adequacy was inversely associated with the severity of pruritus; patients who never had pruritus (n = 16), those who had a reduction in pruritus over three months (n = 16), and those who had prolonged severe pruritus (n = 22) had mean Kt/V values of 1.31, 1.28, and 1.09, respectively.</p><p></p><p class="bulletIndent1">In a second phase of this study, patients who had severe, prolonged pruritus were assigned to receive either increased dialysis (n = 9) or the same dialysis dose (n = 13) for an additional three months, with mean follow-up Kt/V values of 1.19 and 1.07, respectively. The percentage of patients who reported a decrease in pruritus was greater in patients assigned to receive more dialysis compared with those whose dialysis dose did not change (77 versus 8 percent, respectively) [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1">Importantly, the highest Kt/V values reported in this study from 1995 were still lower than the dose that is generally recommended today (ie, a target single-pool Kt/V of 1.4 per thrice weekly hemodialysis session with a minimum delivered single-pool Kt/V of 1.2).</p><p></p><p class="bulletIndent1">Two additional observational studies yielded conflicting results. In one five-year prospective study that included 111 patients, those with Kt/V &lt;1.5 were more likely to have pruritus, and those with Kt/V &gt;1.5 were less likely to have pruritus [<a href="#rid59">59</a>]. By contrast, in a study of a cohort of 105 patients, the mean Kt/V was 1.7 in those without pruritus and 1.82 in those with pruritus [<a href="#rid26">26</a>]. A posited explanation for this observation is that patients with the higher Kt/V had more prolonged contact with dialyzer membranes or silicone tubing, which caused pruritus. Alternatively, treatment times and Kt/V may have been higher among patients with lower residual kidney function or worse metabolic parameters, which could have accounted for the pruritus rather than the longer treatment time, per se.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Biocompatible, high-flux hemodialysis membranes</strong> – Almost all patients on hemodialysis in the United States and other resource-abundant settings are dialyzed with biocompatible, high-flux membranes. However, for the rare patient who is being dialyzed with a bioincompatible and/or low-flux membrane, we switch to a biocompatible, high-flux membrane.</p><p></p><p class="bulletIndent1">Biocompatible dialysis membranes (such as those made with polymethylmethacrylate [PMMA]) may decrease pruritus [<a href="#rid60">60-62</a>]. In the largest study of 30 patients with CKD-aP, the mean pruritus score decreased four weeks after switching to a PMMA dialyzer [<a href="#rid60">60</a>]. Two smaller studies also demonstrated improvement with PMMA membranes [<a href="#rid61">61,62</a>]. </p><p></p><p class="bulletIndent1">Pruritus appears to be more common in patients dialyzed with low-flux dialyzers [<a href="#rid59">59</a>]. In a randomized, double-blind, placebo-controlled crossover study that included 116 patients on hemodialysis, 12 weeks of dialysis with a high-flux dialyzer, but not a conventional flux dialyzer, was associated with a reduction in pruritus from a visual analog score of 6.22 to 2.23 [<a href="#rid63">63</a>]. </p><p></p><p class="headingAnchor" id="H451070"><span class="h3">Parathyroid, phosphate, and calcium</span><span class="headingEndMark"> — </span>We optimize treatment of CKD–mineral and bone disorder (CKD-MBD) in all patients with CKD-aP. The parathyroid hormone (PTH) and phosphate concentrations that should be maintained to prevent or treat CKD-aP are not known; we target the commonly accepted serum values that have been developed for the overall benefit of such patients, and we avoid treatment-associated elevations in serum calcium. Our treatment approaches to secondary hyperparathyroidism and hyperphosphatemia are detailed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/1964.html" rel="external">"Management of secondary hyperparathyroidism in adult nondialysis patients with chronic kidney disease"</a> and  <a class="medical medical_review" href="/z/d/html/1918.html" rel="external">"Management of secondary hyperparathyroidism in adult patients on dialysis"</a> and  <a class="medical medical_review" href="/z/d/html/1942.html" rel="external">"Management of hyperphosphatemia in adults with chronic kidney disease"</a>.)</p><p>Limited data suggest that the treatment of hyperparathyroidism, hyperphosphatemia, and hypercalcemia reduces CKD-aP [<a href="#rid22">22,23</a>]. The best data are from a series of 37 patients on hemodialysis who underwent parathyroidectomy for bone pain, pruritus alone, or bone pain with pruritus [<a href="#rid23">23</a>]. The mean PTH level was 1473 pg/mL before surgery and 33 pg/mL postoperatively. Serum calcium and phosphate concentrations were 11.1 and 6.5 mg/dL preoperatively and 8.4 and 3.8 mg/dL postoperatively. Pruritus quantitated by a visual analog scale decreased from 5.5 to 1.8 although a statistical correlation between pruritus and preoperative levels of calcium, phosphate, or PTH could not be demonstrated.</p><p>However, there are no data that suggest that parathyroidectomy is beneficial in the absence of markedly elevated PTH concentrations such as those present in the study cited above. </p><p>Although the effect of nonsurgical treatment of hyperparathyroidism, such as vitamin D derivatives and calcimimetics, on CKD-aP has not been shown, such agents are standard therapy for secondary hyperparathyroidism and should be employed before parathyroidectomy is considered. Parathyroidectomy should be reserved for patients who have elevated PTH, hypercalcemia, or hyperphosphatemia that is refractory to medical therapy. (See  <a class="medical medical_review" href="/z/d/html/1838.html" rel="external">"Refractory hyperparathyroidism and indications for parathyroidectomy in adult patients on dialysis"</a>.)</p><p class="headingAnchor" id="H452115"><span class="h3">Skin emollients</span><span class="headingEndMark"> — </span>For most patients with CKD-aP, we suggest treatment with a topical emollient. We prefer emollients with a high water content. Because xerosis (dry skin) is common and often may be difficult to detect, we use emollient therapy even in patients without obvious xerosis. We generally treat with an emollient for at least two weeks to gauge efficacy before initiating other medical therapies; the exception is for adequately dialyzed patients who present with severe pruritus, in whom we do not delay additional treatment (see <a class="local">'Sequential therapy for persistent pruritus'</a> below). We typically continue treatment with emollients indefinitely, regardless of initial response, since inadequately treated xerosis may prevent or reduce the efficacy of other therapies. </p><p>Most trials reporting the efficacy of emollients have been small or uncontrolled [<a href="#rid64">64,65</a>]. However, a randomized, double-blind, intraindividual (left versus<strong> </strong>right comparison), multicenter trial compared an oil and water emulsion containing glycerol (15 percent) and paraffin (10 percent) with emulsion alone among 99 patients with moderate to severe uremic xerosis [<a href="#rid66">66</a>]. At seven days, more patients responded to the glycerol/paraffin emulsion than to the emulsion alone with a reduction in pruritus (73 percent versus 44 percent, respectively). Open-label use of the glycerol- and paraffin-containing emulsion on all xerotic areas for 49 days resulted in a substantial improvement of pruritus and quality of life of the patients at study end [<a href="#rid66">66</a>].</p><p>There are no good comparative trials among various emollients for CKD-aP. </p><p class="headingAnchor" id="H655794690"><span class="h2">Sequential therapy for persistent pruritus</span><span class="headingEndMark"> — </span>For patients with continued symptoms despite two weeks of the general measures above (see <a class="local">'General measures in all patients'</a> above), we treat with additional therapy. The exception is for adequately dialyzed patients who present with severe pruritus, in whom we start additional treatment without delay. The interventions below are trialed sequentially, stopping one before starting another. The process concludes when an effective intervention is identified  (<a class="graphic graphic_algorithm graphicRef142585" href="/z/d/graphic/142585.html" rel="external">algorithm 1</a>).</p><p class="headingAnchor" id="H3651531169"><span class="h3">Topical analgesics</span><span class="headingEndMark"> — </span>For patients with CKD-aP who have persistent symptoms despite use of a skin emollient or who present with severe pruritus despite adequate dialysis, we suggest a topical analgesic agent. Topical analgesics should be applied to localized areas of pruritus and should be stopped if an inadequate response is observed after approximately one week. Our preferred topical analgesic agent is <a class="drug drug_general" data-topicid="10226" href="/z/d/drug information/10226.html" rel="external">pramoxine</a>, which is available in over-the-counter preparations and is generally safe. In a randomized trial that included 28 patients on hemodialysis, twice daily application of pramoxine was associated with a greater reduction in pruritus compared with an emollient (61 versus 12 percent, respectively) [<a href="#rid67">67</a>]. </p><p>We do <strong>not</strong> use topical nonsteroidal antiinflammatory drugs (NSAIDs) or <a class="drug drug_general" data-topicid="8840" href="/z/d/drug information/8840.html" rel="external">capsaicin</a> to treat CKD-aP. Topical NSAIDs have not been evaluated as a treatment for CKD-aP and carry a risk of adversely affecting residual kidney function. Capsaicin is a topical analgesic that has been reported to be effective for localized pruritus [<a href="#rid68">68-70</a>]. However, in many patients capsaicin causes an unpleasant (albeit temporary) localized burning/stinging sensation, and existing capsaicin trials have design flaws that hinder their interpretation [<a href="#rid71">71</a>]. </p><p class="headingAnchor" id="H18786081"><span class="h3">Oral antihistamine trial</span><span class="headingEndMark"> — </span>For patients with CKD-aP who do not respond to topical therapy, we suggest oral antihistamine therapy. We stop antihistamines if an inadequate response is observed after approximately one week. We use either <a class="drug drug_general" data-topicid="8544" href="/z/d/drug information/8544.html" rel="external">hydroxyzine</a> (25 mg orally once or twice daily) or <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a> (25 mg orally three to four times daily). Some patients, however, may find these agents overly sedating when taken during the day. For such patients, we suggest trying a less sedating agent, such as <a class="drug drug_general" data-topicid="9572" href="/z/d/drug information/9572.html" rel="external">loratadine</a>, during the day, with the continued use of the sedating antihistamines at night. (See  <a class="medical medical_review" href="/z/d/html/131632.html" rel="external">"Pruritus: Therapies for generalized pruritus", section on 'Role of antihistamines'</a>.)</p><p>The beneficial effects of antihistamines in pruritus are believed to be mediated via both their sedating properties and ability to stabilize mast cell membranes [<a href="#rid72">72</a>]. There are no high-quality data demonstrating efficacy of antihistamines for CKD-aP; our use of these agents is based on their relative safety and tolerability, their low cost, and our clinical experience.</p><p class="headingAnchor" id="H18786088"><span class="h3">Gabapentin and pregabalin</span><span class="headingEndMark"> — </span>For patients with CKD-aP who do not respond to oral antihistamines, we suggest <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>. We stop these agents if an inadequate response is observed after four to six weeks. The preferred initial dose of gabapentin is 100 mg after each dialysis session. The dose may be gradually increased to 300 mg daily, based on response. Pregabalin is initiated at 25 mg daily, and the dose may be gradually increased to 75 mg daily. Gabapentin doses greater than 300 mg daily and pregabalin doses of greater than 75 mg daily are not recommended in patients with stage 5 CKD, whether on dialysis or not. Patients taking gabapentin or pregabalin should be monitored closely for neurologic side effects such as dizziness and somnolence. </p><p>Gabapentinoids are used in a variety of neuropathic pain syndromes and have demonstrated efficacy for the treatment of CKD-aP in a number of relatively small trials [<a href="#rid73">73-82</a>]. In a meta-analysis of randomized controlled trials that included five studies and 297 patients with CKD-aP, treatment with <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> reduced pruritus by approximately five points on a continuous 10-point visual scale [<a href="#rid83">83</a>].</p><p class="headingAnchor" id="H449784"><span class="h2">Refractory pruritus</span><span class="headingEndMark"> — </span>Most patients with CKD-aP will at least partially respond to emollients, topical analgesics, oral antihistamines, or a gabapentinoid. For patients on hemodialysis who are refractory to these agents, we use <a class="drug drug_general" data-topicid="132520" href="/z/d/drug information/132520.html" rel="external">difelikefalin</a>. Other options for refractory CKD-aP include dialysis modification, selective serotonin reuptake inhibitors, and phototherapy.</p><p class="headingAnchor" id="H273914142"><span class="h3">Difelikefalin for patients on hemodialysis</span><span class="headingEndMark"> — </span>For patients on hemodialysis who have moderate to severe CKD-aP that does not respond to other agents, we suggest <a class="drug drug_general" data-topicid="132520" href="/z/d/drug information/132520.html" rel="external">difelikefalin</a>. Difelikefalin is a peripherally restricted selective kappa-opioid agonist that is administered intravenously (0.5 microgram/kg) three times a week at dialysis. We stop difelikefalin if an inadequate response is observed after 12 weeks of treatment. To avoid vascular access complications, we do not administer difelikefalin intravenously in settings other than dialysis. </p><p>Several randomized controlled trials using multiple quantitative measures of pruritus demonstrate modest efficacy of <a class="drug drug_general" data-topicid="132520" href="/z/d/drug information/132520.html" rel="external">difelikefalin</a> [<a href="#rid57">57,84-87</a>]. In a pooled analysis of two randomized controlled trials including 851 patients on maintenance hemodialysis with moderate to severe pruritus, more patients had improved itch intensity at 12 weeks (defined ≥3-point reduction from baseline in the weekly mean score on the 24-hour Worst Itching Intensity Numerical Rating Scale) with difelikefalin compared with placebo (51.1 versus 35.2 percent; p&lt;0.001) [<a href="#rid86">86</a>]. In addition, difelikefalin resulted in greater improvement in itch-related quality of life, an effect that persisted in a 52-week open-label trial extension. Although difelikefalin resulted in clinically meaningful improvement compared with placebo in these trials, patients treated with placebo also experienced substantial reductions in itch symptoms.</p><p>In the pooled trials above, <a class="drug drug_general" data-topicid="132520" href="/z/d/drug information/132520.html" rel="external">difelikefalin</a> was generally well tolerated, with 6.8 percent in the difelikefalin arm withdrawing for adverse events compared with 4 percent with placebo [<a href="#rid88">88</a>]. The most frequent side effects with difelikefalin were diarrhea, dizziness, and nausea. Somnolence was more common in patients receiving difelikefalin compared with placebo (4.2 percent versus 2.4 percent), especially in patients aged 65 years or older (7 percent versus 3 percent). In the first trial included in the pooled analysis, the difelikefalin group did not experience opioid-related adverse effects such as dysphoria, euphoria, hallucinations, or symptoms of withdrawal upon discontinuation of the drug [<a href="#rid57">57</a>]. Other data demonstrate that even higher doses of difelikefalin do not cause respiratory depression [<a href="#rid89">89</a>]. </p><p>Several concerns surround the use of <a class="drug drug_general" data-topicid="132520" href="/z/d/drug information/132520.html" rel="external">difelikefalin</a>. First, long-term efficacy and safety data for difelikefalin are limited. Only a minority of patients in the pooled trials above completed the 52-week open-label trial extension. Second, comparative efficacy data with other medications, such as <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> and <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a>, are needed. Finally, the cost of difelikefalin may complicate accessibility and long-term use [<a href="#rid90">90</a>].</p><p>Another kappa-opioid agonist, nalfurafine, is approved for treating uremic pruritus in Japan. A randomized controlled trial conducted in the United States was terminated due to the inability to enroll sufficient patients [<a href="#rid91">91</a>].</p><p class="headingAnchor" id="H1296485019"><span class="h3">Other therapies</span><span class="headingEndMark"> — </span>If <a class="drug drug_general" data-topicid="132520" href="/z/d/drug information/132520.html" rel="external">difelikefalin</a> is unavailable or ineffective, or if a patient is on peritoneal dialysis, we offer a trial of intensified dialysis. For patients on hemodialysis, switching to hemodiafiltration may be an option in certain settings. Potential alternatives to difelikefalin also include selective serotonin reuptake inhibitors and phototherapy. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Dialysis modification </strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Intensify dialysis</strong> – For patients on hemodialysis or peritoneal dialysis who have severe pruritus despite achieving optimal Kt/V targets and who are highly motivated, the dialysis dose may be increased further as a trial. For patients on thrice weekly hemodialysis who choose intensified dialysis, we generally target a single-pool Kt/V of 1.5 to 1.7 per hemodialysis session. For patients on peritoneal dialysis who choose intensified dialysis, we generally target a total (ie, residual kidney plus peritoneal) Kt/V of 1.9 to 2.1 per week. If an inadequate response is observed after six to eight weeks, we resume the regular dialysis regimen.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Hemodiafiltration for patients on hemodialysis</strong> – Hemodiafiltration is generally not available in the United States. However, if available, switching a patient from hemodialysis to hemodiafiltration may improve pruritus. In a 12-week randomized controlled study including 51 patients, patients undergoing hemodiafiltration had improved pruritus as assessed by visual analog scores and lower beta-2 microglobulin, C-reactive protein, and interleukin 6 levels compared with the group undergoing high-flux hemodialysis [<a href="#rid92">92</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Sertraline</strong> – A trial of the selective serotonin reuptake inhibitor (SSRI) <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> is reasonable in patients with refractory pruritus [<a href="#rid56">56,93-95</a>]. Sertraline should be stopped if an inadequate response is observed after four to six weeks. Antidepressants have been used for the treatment of pruritus in the general (ie, non-CKD) population (see  <a class="medical medical_review" href="/z/d/html/131632.html" rel="external">"Pruritus: Therapies for generalized pruritus", section on 'Antidepressants'</a>). </p><p></p><p class="bulletIndent1">In one uncontrolled study, among 20 nondialysis CKD patients with severe pruritus refractory to antihistamines, 17 responded to <a class="drug drug_general" data-topicid="9886" href="/z/d/drug information/9886.html" rel="external">sertraline</a> after a mean duration of 5.1 weeks [<a href="#rid94">94</a>]. The mean effective daily dose was 35 mg. In a subsequent eight-week randomized, double-blind, placebo-controlled study that included 50 patients on dialysis, the group administered sertraline at 50 mg per day had a greater reduction in pruritus compared with placebo (visual analog score decreased from 9 to 1.8 in the sertraline group versus 8.8 to 3.2 in the placebo group). The benefit of sertraline was noted only after four weeks of treatment [<a href="#rid56">56</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Phototherapy </strong>–<strong> </strong>We generally reserve phototherapy for patients with persistent symptoms who have not responded to or tolerated other options. Ultraviolet B (UVB) irradiation may be effective in the treatment of CKD-aP, as noted in small or uncontrolled studies [<a href="#rid39">39,96-99</a>]. As an example, in one study, 8 of 10 patients with refractory pruritus reported improvement in symptoms after UVB therapy [<a href="#rid97">97</a>]. The UVB dose was initiated at 200 to 400 mJ/cm<sup>2</sup> and increased by 100 mJ/cm<sup>2</sup> at each session to a maximum daily dose of 1500 mJ/cm<sup>2</sup>. Recurrence of symptoms following cessation of therapy may be a problem; in this study, four patients who responded initially had recurrence of symptoms.</p><p></p><p class="bulletIndent1">The beneficial effects of UVB therapy are thought to be due to a decrease in proinflammatory cytokine levels and induction of mast cell apoptosis [<a href="#rid100">100</a>]. Specific UVB treatment protocols are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/13745.html" rel="external">"UVB phototherapy (broadband and narrowband)"</a>.)</p><p></p><p class="bulletIndent1">UVB therapy is associated with an increased risk of carcinogenesis and should not be used in patients who are on immunosuppressive therapy. The carcinogenic potential of UVB irradiation is an issue that should be discussed with all patients for whom such therapy is considered [<a href="#rid35">35</a>]. UVB therapy should not be used in patients with systemic lupus erythematosus, because of the known photosensitivity of such patients. (See  <a class="medical medical_review" href="/z/d/html/4666.html" rel="external">"Overview of cutaneous lupus erythematosus"</a>.)</p><p></p><p class="headingAnchor" id="H1233507533"><span class="h2">Therapies of limited use</span><span class="headingEndMark"> — </span>Many other agents have been studied as therapies for CKD-aP. However, we do not advocate their use because of insufficient data and/or side effects. If clinicians use these therapies, they should prioritize agents with a minimal side effect profile and should stop treatment after inadequate response.  </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Mixed opioid receptor agonists and antagonists</strong> – The mixed mu-antagonists/kappa-agonists <a class="drug drug_general" data-topicid="9676" href="/z/d/drug information/9676.html" rel="external">nalbuphine</a> and <a class="drug drug_general" data-topicid="9179" href="/z/d/drug information/9179.html" rel="external">butorphanol</a> and the opioid receptor antagonist <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> have been studied for the treatment of CKD-aP:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In 15 patients on hemodialysis suffering from pruritus, an open-label, multiple escalating-dose study of the mixed mu-antagonist/kappa-agonist <a class="drug drug_general" data-topicid="9676" href="/z/d/drug information/9676.html" rel="external">nalbuphine</a> showed reduction in the mean visual analog score from 4 to 1.2 at 180 mg/day and 0.4 at 240 mg/day [<a href="#rid101">101</a>]. In an eight-week randomized, placebo-controlled trial, nalbuphine 120 mg twice a day, but not nalbuphine 60 mg twice a day, decreased pruritus as assessed by a numerical rating scale [<a href="#rid55">55</a>]. However, nalbuphine was poorly tolerated, with a high dropout rate (approximately 25 percent) in the active arms of the trial compared with placebo.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A beneficial effect of intranasal <a class="drug drug_general" data-topicid="9179" href="/z/d/drug information/9179.html" rel="external">butorphanol</a>, a kappa-opioid receptor agonist and mu-receptor antagonist, was demonstrated in a limited, five-patient case series [<a href="#rid102">102</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although a few short-term studies suggested that <a class="drug drug_general" data-topicid="9679" href="/z/d/drug information/9679.html" rel="external">naltrexone</a> was effective for CKD-aP [<a href="#rid103">103-106</a>], no benefit was demonstrated in a randomized, double-blind, placebo-controlled crossover study [<a href="#rid11">11</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Other</strong> – Various other therapies have been studied, including omega-6 fatty acid [<a href="#rid107">107</a>], omega-3 fatty acid [<a href="#rid108">108,109</a>], turmeric [<a href="#rid110">110</a>], zinc [<a href="#rid111">111</a>], acupuncture [<a href="#rid112">112</a>], activated charcoal [<a href="#rid113">113,114</a>], selective inhibitors 5-hydroxytryptamine receptors [<a href="#rid115">115</a>], oral <a class="drug drug_general" data-topicid="9300" href="/z/d/drug information/9300.html" rel="external">cromolyn</a> sodium [<a href="#rid116">116,117</a>], <a class="drug drug_general" data-topicid="9258" href="/z/d/drug information/9258.html" rel="external">cholestyramine</a> [<a href="#rid118">118</a>], nicergoline [<a href="#rid119">119</a>], <a class="drug drug_general" data-topicid="10095" href="/z/d/drug information/10095.html" rel="external">thalidomide</a> [<a href="#rid38">38</a>], <a class="drug drug_general" data-topicid="16764" href="/z/d/drug information/16764.html" rel="external">ketotifen</a> [<a href="#rid49">49</a>], <a class="drug drug_general" data-topicid="112484" href="/z/d/drug information/112484.html" rel="external">dupilumab</a> [<a href="#rid120">120,121</a>], <a class="drug drug_general" data-topicid="9539" href="/z/d/drug information/9539.html" rel="external">montelukast</a> [<a href="#rid122">122,123</a>], and topical agents such as gamma linolenic acid [<a href="#rid124">124</a>], sericin cream [<a href="#rid125">125</a>], endocannabinoids [<a href="#rid126">126</a>], topical vitamin D [<a href="#rid127">127</a>], cromolyn sodium [<a href="#rid128">128</a>], and topical <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> [<a href="#rid40">40,129-131</a>].</p><p></p><p class="headingAnchor" id="H3797076944"><span class="h1">IMPACT OF TRANSPLANTATION</span><span class="headingEndMark"> — </span>Kidney transplantation is definitive therapy for CKD-aP. As an example, one retrospective study reported that generalized pruritus completely disappeared following successful transplantation [<a href="#rid132">132</a>]. For patients who are undecided about whether to undergo a kidney transplant, persistent pruritus may provide incentive.</p><p class="headingAnchor" id="H1912349310"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/118799.html" rel="external">"Society guideline links: Pruritus"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112932.html" rel="external">"Society guideline links: Dialysis"</a>.)</p><p class="headingAnchor" id="H656928"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview </strong>– Pruritus is common among patients with stage 5 chronic kidney disease (CKD). The etiology is not known. CKD-associated pruritus (CKD-aP) has been associated with inadequate dialysis and abnormal bone and mineral metabolism as well as xerosis (dry skin caused by sweat gland atrophy). (See <a class="local">'Introduction'</a> above and <a class="local">'Risk factors and associations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis </strong>– Our approach to diagnosing CKD-aP is based on the degree of kidney dysfunction. (See <a class="local">'Diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – Treatment involves a stepwise approach that depends upon the severity of symptoms and the response to sequential therapies  (<a class="graphic graphic_algorithm graphicRef142585" href="/z/d/graphic/142585.html" rel="external">algorithm 1</a>). (See <a class="local">'Management'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>General measures in all patients</strong> – General measures for all patients with CKD-aP include the following (see <a class="local">'General measures in all patients'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients on dialysis with Kt/V values that are less than generally accepted Kt/V targets for hemodialysis and peritoneal dialysis, we increase the dose of dialysis to meet those targets. </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We optimize treatment of CKD-mineral and bone disorder (CKD-MBD).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For most patients with CKD-aP, we suggest treatment with a topical emollient (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We typically continue treatment with emollients indefinitely, regardless of initial response, since inadequately treated xerosis may prevent or reduce the efficacy of other therapies. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Sequential therapy for persistent pruritus </strong>–<strong> </strong>For patients with continued symptoms despite two weeks of the general measures above, we treat with additional therapy. The exception is for adequately dialyzed patients who present with severe pruritus, in whom we start additional treatment without delay. The interventions below are trialed sequentially, stopping each one before starting another. The process concludes when an effective intervention is identified. (See <a class="local">'Sequential therapy for persistent pruritus'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with CKD-aP who have persistent symptoms despite use of a skin emollient, or who present with severe pruritus despite adequate dialysis, we suggest a topical analgesic agent rather than oral agents (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We stop this agent if an inadequate response is observed after approximately one week. (See <a class="local">'Topical analgesics'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with CKD-aP who do not respond to topical therapy, we suggest oral antihistamine therapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We stop antihistamines if an inadequate response is observed after approximately one week. (See <a class="local">'Oral antihistamine trial'</a> above.)</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with CKD-aP who do not respond to oral antihistamines, we suggest <a class="drug drug_general" data-topicid="8483" href="/z/d/drug information/8483.html" rel="external">gabapentin</a> or <a class="drug drug_general" data-topicid="9473" href="/z/d/drug information/9473.html" rel="external">pregabalin</a> (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). We stop these agents if an inadequate response is observed after four to six weeks. (See <a class="local">'Gabapentin and pregabalin'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Refractory pruritus </strong>– For patients on hemodialysis who have moderate to severe CKD-aP that does not respond to other agents, we suggest <a class="drug drug_general" data-topicid="132520" href="/z/d/drug information/132520.html" rel="external">difelikefalin</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). We stop difelikefalin if an inadequate response is observed after 12 weeks of treatment. Other options for refractory CKD-aP include dialysis intensification, selective serotonin reuptake inhibitors (SSRIs), and phototherapy. (See <a class="local">'Difelikefalin for patients on hemodialysis'</a> above and <a class="local">'Other therapies'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Impact of transplantation </strong>– CKD-aP resolves following kidney transplantation. For transplant candidates who are undecided, persistent pruritus may provide additional incentive to undergo transplantation. (See <a class="local">'Impact of transplantation'</a> above.)</p><p></p><p class="headingAnchor" id="H176099932"><span class="h1">ACKNOWLEDGMENT</span></p><p>We are saddened by the death of Sidney Kobrin, MD, who passed away in October 2023. UpToDate wishes to acknowledge Dr. Kobrin's many valuable contributions, including his past work as an author for this topic.</p><p>The UpToDate editorial staff acknowledges Theodore Tzeremas, MD, who contributed to earlier versions of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Titapiccolo JI, Lonati C, Goethel-Paal B, et al. Chronic kidney disease-associated pruritus (CKD-aP) is associated with worse quality of life and increased healthcare utilization among dialysis patients. Qual Life Res 2023; 32:2939.</a></li><li><a class="nounderline abstract_t">Menzaghi F, Vernon MK, Mattera M, et al. The Burden of Pruritus Associated With CKD: A Mixed Methods Analysis Among Patients Undergoing Dialysis. Kidney Med 2023; 5:100696.</a></li><li><a class="nounderline abstract_t">Sukul N, Zhao J, Pisoni RL, et al. Pruritus in Hemodialysis Patients: Longitudinal Associations With Clinical and Patient-Reported Outcomes. Am J Kidney Dis 2023; 82:666.</a></li><li><a class="nounderline abstract_t">Patel TS, Freedman BI, Yosipovitch G. An update on pruritus associated with CKD. Am J Kidney Dis 2007; 50:11.</a></li><li><a class="nounderline abstract_t">Nielsen T, Andersen KE, Kristiansen J. Pruritus and xerosis in patients with chronic renal failure. Dan Med Bull 1980; 27:269.</a></li><li><a class="nounderline abstract_t">Bencini PL, Montagnino G, Citterio A, et al. Cutaneous abnormalities in uremic patients. Nephron 1985; 40:316.</a></li><li><a class="nounderline abstract_t">Balaskas EV, Chu M, Uldall RP, et al. Pruritus in continuous ambulatory peritoneal dialysis and hemodialysis patients. Perit Dial Int 1993; 13 Suppl 2:S527.</a></li><li><a class="nounderline abstract_t">Wikström B. Itchy skin--a clinical problem for haemodialysis patients. Nephrol Dial Transplant 2007; 22 Suppl 5:v3.</a></li><li><a class="nounderline abstract_t">Narita I, Alchi B, Omori K, et al. Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients. Kidney Int 2006; 69:1626.</a></li><li><a class="nounderline abstract_t">Pisoni RL, Wikström B, Elder SJ, et al. Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant 2006; 21:3495.</a></li><li><a class="nounderline abstract_t">Pauli-Magnus C, Mikus G, Alscher DM, et al. Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study. J Am Soc Nephrol 2000; 11:514.</a></li><li><a class="nounderline abstract_t">Sukul N, Karaboyas A, Csomor PA, et al. Self-reported Pruritus and Clinical, Dialysis-Related, and Patient-Reported Outcomes in Hemodialysis Patients. Kidney Med 2021; 3:42.</a></li><li><a class="nounderline abstract_t">Rayner HC, Larkina M, Wang M, et al. International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis. Clin J Am Soc Nephrol 2017; 12:2000.</a></li><li><a class="nounderline abstract_t">Mettang T, Fritz P, Weber J, et al. Uremic pruritus in patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). The role of plasma histamine and skin mast cells. Clin Nephrol 1990; 34:136.</a></li><li><a class="nounderline abstract_t">Tessari G, Dalle Vedove C, Loschiavo C, et al. The impact of pruritus on the quality of life of patients undergoing dialysis: a single centre cohort study. J Nephrol 2009; 22:241.</a></li><li><a class="nounderline abstract_t">Schwab M, Mikus G, Mettang T. Ura mischer pruritus im Kindes- und Jugendalter. Monatsschr Kinderheilkd 1999; 147:232.</a></li><li><a class="nounderline abstract_t">Min JW, Kim SH, Kim YO, et al. Comparison of uremic pruritus between patients undergoing hemodialysis and peritoneal dialysis. Kidney Res Clin Pract 2016; 35:107.</a></li><li><a class="nounderline abstract_t">Wu HY, Peng YS, Chen HY, et al. A Comparison of Uremic Pruritus in Patients Receiving Peritoneal Dialysis and Hemodialysis. Medicine (Baltimore) 2016; 95:e2935.</a></li><li><a class="nounderline abstract_t">Sukul N, Speyer E, Tu C, et al. Pruritus and Patient Reported Outcomes in Non-Dialysis CKD. Clin J Am Soc Nephrol 2019; 14:673.</a></li><li><a class="nounderline abstract_t">Hiroshige K, Kabashima N, Takasugi M, Kuroiwa A. Optimal dialysis improves uremic pruritus. Am J Kidney Dis 1995; 25:413.</a></li><li><a class="nounderline abstract_t">Masi CM, Cohen EP. Dialysis efficacy and itching in renal failure. Nephron 1992; 62:257.</a></li><li><a class="nounderline abstract_t">Massry SG, Popovtzer MM, Coburn JW, et al. Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. Disappearance of itching after subtotal parathyroidectomy. N Engl J Med 1968; 279:697.</a></li><li><a class="nounderline abstract_t">Chou FF, Ho JC, Huang SC, Sheen-Chen SM. A study on pruritus after parathyroidectomy for secondary hyperparathyroidism. J Am Coll Surg 2000; 190:65.</a></li><li><a class="nounderline abstract_t">Hu T, Wang B, Liao X, Wang S. Clinical features and risk factors of pruritus in patients with chronic renal failure. Exp Ther Med 2019; 18:964.</a></li><li><a class="nounderline abstract_t">Blachley JD, Blankenship DM, Menter A, et al. Uremic pruritus: skin divalent ion content and response to ultraviolet phototherapy. Am J Kidney Dis 1985; 5:237.</a></li><li><a class="nounderline abstract_t">Duque MI, Thevarajah S, Chan YH, et al. Uremic pruritus is associated with higher kt/V and serum calcium concentration. Clin Nephrol 2006; 66:184.</a></li><li><a class="nounderline abstract_t">Rosenthal SR. Uremic dermatitis. Arch Dermatol Syphil 1931; 23:934.</a></li><li><a class="nounderline abstract_t">CAWLEY EP, HOCH-LIGHETI C, BOND GM. The eccrine sweat glands of patients in uremia. Arch Dermatol 1961; 84:889.</a></li><li><a class="nounderline abstract_t">Friga V, Linos A, Linos DA. Is aluminum toxicity responsible for uremic pruritus in chronic hemodialysis patients? Nephron 1997; 75:48.</a></li><li><a class="nounderline abstract_t">Navarro-González JF, Mora-Fernández C, García-Pérez J. Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis. Semin Dial 2009; 22:37.</a></li><li><a class="nounderline abstract_t">Carmichael AJ, McHugh MM, Martin AM, Farrow M. Serological markers of renal itch in patients receiving long term haemodialysis. Br Med J (Clin Res Ed) 1988; 296:1575.</a></li><li><a class="nounderline abstract_t">De Marchi S, Cecchin E, Villalta D, et al. Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia. N Engl J Med 1992; 326:969.</a></li><li><a class="nounderline abstract_t">Berne B, Vahlquist A, Fischer T, et al. UV treatment of uraemic pruritus reduces the vitamin A content of the skin. Eur J Clin Invest 1984; 14:203.</a></li><li><a class="nounderline abstract_t">Charlesworth EN, Beltrani VS. Pruritic dermatoses: overview of etiology and therapy. Am J Med 2002; 113 Suppl 9A:25S.</a></li><li><a class="nounderline abstract_t">Kuypers DR. Skin problems in chronic kidney disease. Nat Clin Pract Nephrol 2009; 5:157.</a></li><li><a class="nounderline abstract_t">Mettang T, Pauli-Magnus C, Alscher DM. Uraemic pruritus--new perspectives and insights from recent trials. Nephrol Dial Transplant 2002; 17:1558.</a></li><li><a class="nounderline abstract_t">Kimmel M, Alscher DM, Dunst R, et al. The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients. Nephrol Dial Transplant 2006; 21:749.</a></li><li><a class="nounderline abstract_t">Silva SR, Viana PC, Lugon NV, et al. Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial. Nephron 1994; 67:270.</a></li><li><a class="nounderline abstract_t">Gilchrest BA, Rowe JW, Brown RS, et al. Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action. Ann Intern Med 1979; 91:17.</a></li><li><a class="nounderline abstract_t">Kuypers DR, Claes K, Evenepoel P, et al. A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy. Nephrol Dial Transplant 2004; 19:1895.</a></li><li><a class="nounderline abstract_t">Fallahzadeh MK, Roozbeh J, Geramizadeh B, Namazi MR. Interleukin-2 serum levels are elevated in patients with uremic pruritus: a novel finding with practical implications. Nephrol Dial Transplant 2011; 26:3338.</a></li><li><a class="nounderline abstract_t">Virga G, Visentin I, La Milia V, Bonadonna A. Inflammation and pruritus in haemodialysis patients. Nephrol Dial Transplant 2002; 17:2164.</a></li><li><a class="nounderline abstract_t">Yosipovitch G, Greaves MW, Schmelz M. Itch. Lancet 2003; 361:690.</a></li><li><a class="nounderline abstract_t">Umeuchi H, Togashi Y, Honda T, et al. Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system. Eur J Pharmacol 2003; 477:29.</a></li><li><a class="nounderline abstract_t">Ikoma A, Steinhoff M, Ständer S, et al. The neurobiology of itch. Nat Rev Neurosci 2006; 7:535.</a></li><li class="breakAll">Kumagai H, Saruta T, Matsukawa S, et al. Prospects for a novel kappa-opioid receptor agonist, TRK-820 in uremic pruritus. In: Itch, Basic Mechanisms and Therapy, Yosipovitch G, Greaves MW, Fleischer JA, McGlone F (Eds), Dekker, New York 2004. p.286.</li><li><a class="nounderline abstract_t">Andrew D, Craig AD. Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch. Nat Neurosci 2001; 4:72.</a></li><li><a class="nounderline abstract_t">Hori T, Oka T, Hosoi M, Aou S. Pain modulatory actions of cytokines and prostaglandin E2 in the brain. Ann N Y Acad Sci 1998; 840:269.</a></li><li><a class="nounderline abstract_t">Francos GC, Kauh YC, Gittlen SD, et al. Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus. Int J Dermatol 1991; 30:884.</a></li><li><a class="nounderline abstract_t">Mistik S, Utas S, Ferahbas A, et al. An epidemiology study of patients with uremic pruritus. J Eur Acad Dermatol Venereol 2006; 20:672.</a></li><li><a class="nounderline abstract_t">Young AW Jr, Sweeney EW, David DS, et al. Dermatologic evaluation of pruritus in patients on hemodialysis. N Y State J Med 1973; 73:2670.</a></li><li><a class="nounderline abstract_t">Yosipovitch G, Zucker I, Boner G, et al. A questionnaire for the assessment of pruritus: validation in uremic patients. Acta Derm Venereol 2001; 81:108.</a></li><li><a class="nounderline abstract_t">Zucker I, Yosipovitch G, David M, et al. Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease. J Am Acad Dermatol 2003; 49:842.</a></li><li><a class="nounderline abstract_t">Papa CM. Winter itch, dry skin. J Med Soc N J 1980; 77:817.</a></li><li><a class="nounderline abstract_t">Mathur VS, Kumar J, Crawford PW, et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus. Am J Nephrol 2017; 46:450.</a></li><li><a class="nounderline abstract_t">Pakfetrat M, Malekmakan L, Hashemi N, Tadayon T. Sertraline can reduce uremic pruritus in hemodialysis patient: A double blind randomized clinical trial from Southern Iran. Hemodial Int 2018; 22:103.</a></li><li><a class="nounderline abstract_t">Fishbane S, Jamal A, Munera C, et al. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus. N Engl J Med 2020; 382:222.</a></li><li><a class="nounderline abstract_t">Liakopoulos V, Krishnan M, Stefanidis I, et al. Improvement in uremic symptoms after increasing daily dialysate volume in patients on chronic peritoneal dialysis with declining renal function. Int Urol Nephrol 2004; 36:437.</a></li><li><a class="nounderline abstract_t">Ko MJ, Wu HY, Chen HY, et al. Uremic pruritus, dialysis adequacy, and metabolic profiles in hemodialysis patients: a prospective 5-year cohort study. PLoS One 2013; 8:e71404.</a></li><li><a class="nounderline abstract_t">Lin HH, Liu YL, Liu JH, et al. Uremic pruritus, cytokines, and polymethylmethacrylate artificial kidney. Artif Organs 2008; 32:468.</a></li><li><a class="nounderline abstract_t">Kato A, Takita T, Furuhashi M, et al. Polymethylmethacrylate efficacy in reduction of renal itching in hemodialysis patients: crossover study and role of tumor necrosis factor-alpha. Artif Organs 2001; 25:441.</a></li><li><a class="nounderline abstract_t">Aucella F, Vigilante M, Gesuete A, et al. Uraemic itching: do polymethylmethacrylate dialysis membranes play a role? Nephrol Dial Transplant 2007; 22 Suppl 5:v8.</a></li><li><a class="nounderline abstract_t">Chen ZJ, Cao G, Tang WX, et al. A randomized controlled trial of high-permeability haemodialysis against conventional haemodialysis in the treatment of uraemic pruritus. Clin Exp Dermatol 2009; 34:679.</a></li><li><a class="nounderline abstract_t">Morton CA, Lafferty M, Hau C, et al. Pruritus and skin hydration during dialysis. Nephrol Dial Transplant 1996; 11:2031.</a></li><li><a class="nounderline abstract_t">Okada K, Matsumoto K. Effect of skin care with an emollient containing a high water content on mild uremic pruritus. Ther Apher Dial 2004; 8:419.</a></li><li><a class="nounderline abstract_t">Balaskas E, Szepietowski JC, Bessis D, et al. Randomized, double-blind study with glycerol and paraffin in uremic xerosis. Clin J Am Soc Nephrol 2011; 6:748.</a></li><li><a class="nounderline abstract_t">Young TA, Patel TS, Camacho F, et al. A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients. J Dermatolog Treat 2009; 20:76.</a></li><li><a class="nounderline abstract_t">Tarng DC, Cho YL, Liu HN, Huang TP. Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream. Nephron 1996; 72:617.</a></li><li><a class="nounderline abstract_t">Breneman DL, Cardone JS, Blumsack RF, et al. Topical capsaicin for treatment of hemodialysis-related pruritus. J Am Acad Dermatol 1992; 26:91.</a></li><li><a class="nounderline abstract_t">Cho YL, Liu HN, Huang TP, Tarng DC. Uremic pruritus: roles of parathyroid hormone and substance P. J Am Acad Dermatol 1997; 36:538.</a></li><li><a class="nounderline abstract_t">Gooding SM, Canter PH, Coelho HF, et al. Systematic review of topical capsaicin in the treatment of pruritus. Int J Dermatol 2010; 49:858.</a></li><li><a class="nounderline abstract_t">Russo GE, Spaziani M, Guidotti C, et al. [Pruritus in chronic uremic patients in periodic hemodialysis. Treatment with terfenadine (an antagonist of histamine H1 receptors)]. Minerva Urol Nefrol 1986; 38:443.</a></li><li><a class="nounderline abstract_t">Gunal AI, Ozalp G, Yoldas TK, et al. Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial. Nephrol Dial Transplant 2004; 19:3137.</a></li><li><a class="nounderline abstract_t">Naini AE, Harandi AA, Khanbabapour S, et al. Gabapentin: a promising drug for the treatment of uremic pruritus. Saudi J Kidney Dis Transpl 2007; 18:378.</a></li><li><a class="nounderline abstract_t">Manenti L, Vaglio A, Costantino E, et al. Gabapentin in the treatment of uremic itch: an index case and a pilot evaluation. J Nephrol 2005; 18:86.</a></li><li><a class="nounderline abstract_t">Amirkhanlou S, Rashedi A, Taherian J, et al. Comparison of Gabapentin and Ketotifen in Treatment of Uremic Pruritus in Hemodialysis Patients. Pak J Med Sci 2016; 32:22.</a></li><li><a class="nounderline abstract_t">Nofal E, Farag F, Nofal A, et al. Gabapentin: A promising therapy for uremic pruritus in hemodialysis patients: A randomized-controlled trial and review of literature. J Dermatolog Treat 2016; 27:515.</a></li><li><a class="nounderline abstract_t">Shavit L, Grenader T, Lifschitz M, Slotki I. Use of pregabalin in the management of chronic uremic pruritus. J Pain Symptom Manage 2013; 45:776.</a></li><li><a class="nounderline abstract_t">Aperis G, Paliouras C, Zervos A, et al. The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients. J Ren Care 2010; 36:180.</a></li><li><a class="nounderline abstract_t">Yue J, Jiao S, Xiao Y, et al. Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study. Int Urol Nephrol 2015; 47:161.</a></li><li><a class="nounderline abstract_t">Foroutan N, Etminan A, Nikvarz N, Shojai Shahrokh Abadi M. Comparison of pregabalin with doxepin in the management of uremic pruritus: a randomized single blind clinical trial. Hemodial Int 2017; 21:63.</a></li><li><a class="nounderline abstract_t">Solak Y, Biyik Z, Atalay H, et al. Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study. Nephrology (Carlton) 2012; 17:710.</a></li><li><a class="nounderline abstract_t">Hercz D, Jiang SH, Webster AC. Interventions for itch in people with advanced chronic kidney disease. Cochrane Database Syst Rev 2020; 12:CD011393.</a></li><li><a class="nounderline abstract_t">Narita I, Tsubakihara Y, Uchiyama T, et al. Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial. JAMA Netw Open 2022; 5:e2210339.</a></li><li><a class="nounderline abstract_t">Fishbane S, Mathur V, Germain MJ, et al. Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients. Kidney Int Rep 2020; 5:600.</a></li><li><a class="nounderline abstract_t">Topf J, Wooldridge T, McCafferty K, et al. Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies. Kidney Med 2022; 4:100512.</a></li><li><a class="nounderline abstract_t">Narita I, Tsubakihara Y, Takahashi N, et al. Difelikefalin for Hemodialysis Patients with Pruritus in Japan. NEJM Evid 2023; 2.</a></li><li><a class="nounderline abstract_t">Fishbane S, Wen W, Munera C, et al. Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program. Kidney Med 2022; 4:100513.</a></li><li><a class="nounderline abstract_t">Viscusi ER, Torjman MC, Munera CL, et al. Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: A randomized, double-blind, placebo-controlled trial. Clin Transl Sci 2021; 14:1886.</a></li><li><a class="nounderline abstract_t">Watnick S, Butler CR. Difelikefalin: A Novel Therapy for Dialysis Patient Care. Kidney Med 2022; 4:100519.</a></li><li><a class="nounderline abstract_t">Jaiswal D, Uzans D, Hayden J, et al. Targeting the Opioid Pathway for Uremic Pruritus: A Systematic Review and Meta-analysis. Can J Kidney Health Dis 2016; 3:2054358116675345.</a></li><li><a class="nounderline abstract_t">Jiang X, Ji F, Chen ZW, Huang QL. Comparison of high-flux hemodialysis with hemodialysis filtration in treatment of uraemic pruritus: a randomized controlled trial. Int Urol Nephrol 2016; 48:1533.</a></li><li><a class="nounderline abstract_t">Shakiba M, Sanadgol H, Azmoude HR, et al. Effect of sertraline on uremic pruritus improvement in ESRD patients. Int J Nephrol 2012; 2012:363901.</a></li><li><a class="nounderline abstract_t">Chan KY, Li CW, Wong H, et al. Use of sertraline for antihistamine-refractory uremic pruritus in renal palliative care patients. J Palliat Med 2013; 16:966.</a></li><li><a class="nounderline abstract_t">Elsayed MM, Elgohary IE, Abdelhamid HHS, Zaki SA. The effectiveness of sertraline in alleviating uremic pruritus in hemodialysis patients: a randomized clinical trial. BMC Nephrol 2023; 24:155.</a></li><li><a class="nounderline abstract_t">Szepietowski JC, Schwartz RA. Uremic pruritus. Int J Dermatol 1998; 37:247.</a></li><li><a class="nounderline abstract_t">Ada S, Seçkin D, Budakoğlu I, Ozdemir FN. Treatment of uremic pruritus with narrowband ultraviolet B phototherapy: an open pilot study. J Am Acad Dermatol 2005; 53:149.</a></li><li><a class="nounderline abstract_t">Sherjeena PB, Binitha MP, Rajan U, et al. A controlled trial of narrowband ultraviolet B phototherapy for the treatment of uremic pruritus. Indian J Dermatol Venereol Leprol 2017; 83:247.</a></li><li><a class="nounderline abstract_t">Kee YK, Jeon HJ, Oh J, Shin DH. Vitamin D and narrowband ultraviolet B phototherapy for chronic kidney disease-associated pruritus. Kidney Res Clin Pract 2023.</a></li><li><a class="nounderline abstract_t">Szepietowski JC, Morita A, Tsuji T. Ultraviolet B induces mast cell apoptosis: a hypothetical mechanism of ultraviolet B treatment for uraemic pruritus. Med Hypotheses 2002; 58:167.</a></li><li><a class="nounderline abstract_t">Hawi A, Alcorn H Jr, Berg J, et al. Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus. BMC Nephrol 2015; 16:47.</a></li><li><a class="nounderline abstract_t">Dawn AG, Yosipovitch G. Butorphanol for treatment of intractable pruritus. J Am Acad Dermatol 2006; 54:527.</a></li><li><a class="nounderline abstract_t">Bernstein JE, Swift R. Relief of intractable pruritus with naloxone. Arch Dermatol 1979; 115:1366.</a></li><li><a class="nounderline abstract_t">Andersen LW, Friedberg M, Lokkegaard N. Naloxone in the treatment of uremic pruritus: a case history. Clin Nephrol 1984; 21:355.</a></li><li><a class="nounderline abstract_t">Peer G, Kivity S, Agami O, et al. Randomised crossover trial of naltrexone in uraemic pruritus. Lancet 1996; 348:1552.</a></li><li><a class="nounderline abstract_t">Legroux-Crespel E, Clèdes J, Misery L. A comparative study on the effects of naltrexone and loratadine on uremic pruritus. Dermatology 2004; 208:326.</a></li><li><a class="nounderline abstract_t">Yoshimoto-Furuie K, Yoshimoto K, Tanaka T, et al. Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uremic skin symptoms in hemodialysis patients. Nephron 1999; 81:151.</a></li><li><a class="nounderline abstract_t">Forouhari A, Moghtaderi M, Raeisi S, et al. Pruritus-reducing effects of omega-3 fatty acids in hemodialysis patients: A cross-over randomized clinical trial. Hemodial Int 2022; 26:408.</a></li><li><a class="nounderline abstract_t">Ghanei E, Zeinali J, Borghei M, Homayouni M. Efficacy of omega-3 fatty acids supplementation in treatment of uremic pruritus in hemodialysis patients: a double-blind randomized controlled trial. Iran Red Crescent Med J 2012; 14:515.</a></li><li><a class="nounderline abstract_t">Pakfetrat M, Basiri F, Malekmakan L, Roozbeh J. Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial. J Nephrol 2014; 27:203.</a></li><li><a class="nounderline abstract_t">Najafabadi MM, Faghihi G, Emami A, et al. Zinc sulfate for relief of pruritus in patients on maintenance hemodialysis. Ther Apher Dial 2012; 16:142.</a></li><li><a class="nounderline abstract_t">Zhang L, Li Y, Xiao X, et al. Acupuncture for Uremic Pruritus: A Systematic Review and Meta-Analysis. J Pain Symptom Manage 2023; 65:e51.</a></li><li><a class="nounderline abstract_t">Pederson JA, Matter BJ, Czerwinski AW, Llach F. Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal. Ann Intern Med 1980; 93:446.</a></li><li><a class="nounderline abstract_t">Giovannetti S, Barsotti G, Cupisti A, et al. Oral activated charcoal in patients with uremic pruritus. Nephron 1995; 70:193.</a></li><li><a class="nounderline abstract_t">Layegh P, Mojahedi MJ, Malekshah PE, et al. Effect of oral granisetron in uremic pruritus. Indian J Dermatol Venereol Leprol 2007; 73:231.</a></li><li><a class="nounderline abstract_t">Rosner MH. Cromolyn sodium: a potential therapy for uremic pruritus? Hemodial Int 2006; 10:189.</a></li><li><a class="nounderline abstract_t">Vessal G, Sagheb MM, Shilian S, et al. Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: a double-blind placebo-controlled study. Nephrol Dial Transplant 2010; 25:1541.</a></li><li><a class="nounderline abstract_t">Silverberg DS, Iaina A, Reisin E, et al. Cholestyramine in uraemic pruritus. Br Med J 1977; 1:752.</a></li><li><a class="nounderline abstract_t">Bousquet J, Rivory JP, Maheut M, et al. Double-blind, placebo-controlled study of nicergoline in the treatment of pruritus in patients receiving maintenance hemodialysis. J Allergy Clin Immunol 1989; 83:825.</a></li><li><a class="nounderline abstract_t">Zhai LL, Savage KT, Qiu CC, et al. Chronic Pruritus Responding to Dupilumab-A Case Series. Medicines (Basel) 2019; 6.</a></li><li><a class="nounderline abstract_t">Silverberg JI, Brieva J. A successful case of dupilumab treatment for severe uremic pruritus. JAAD Case Rep 2019; 5:339.</a></li><li><a class="nounderline abstract_t">Nasrollahi AR, Miladipour A, Ghanei E, et al. Montelukast for treatment of refractory pruritus in patients on hemodialysis. Iran J Kidney Dis 2007; 1:73.</a></li><li><a class="nounderline abstract_t">Mahmudpour M, Roozbeh J, Raiss Jalali GA, et al. Therapeutic Effect of Montelukast for Treatment of Uremic Pruritus in Hemodialysis Patients. Iran J Kidney Dis 2017; 11:50.</a></li><li><a class="nounderline abstract_t">Chen YC, Chiu WT, Wu MS. Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus. Am J Kidney Dis 2006; 48:69.</a></li><li><a class="nounderline abstract_t">Aramwit P, Keongamaroon O, Siritientong T, et al. Sericin cream reduces pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled experimental study. BMC Nephrol 2012; 13:119.</a></li><li><a class="nounderline abstract_t">Szepietowski JC, Szepietowski T, Reich A. Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study. Acta Dermatovenerol Croat 2005; 13:97.</a></li><li><a class="nounderline abstract_t">Jung KE, Woo YR, Lee JS, et al. Effect of topical vitamin D on chronic kidney disease-associated pruritus: An open-label pilot study. J Dermatol 2015; 42:800.</a></li><li><a class="nounderline abstract_t">Feily A, Dormanesh B, Ghorbani AR, et al. Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: a randomized double-blind study in 60 patients. Int J Clin Pharmacol Ther 2012; 50:510.</a></li><li><a class="nounderline abstract_t">Pauli-Magnus C, Klumpp S, Alscher DM, et al. Short-term efficacy of tacrolimus ointment in severe uremic pruritus. Perit Dial Int 2000; 20:802.</a></li><li><a class="nounderline abstract_t">Duque MI, Yosipovitch G, Fleischer AB Jr, et al. Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study. J Am Acad Dermatol 2005; 52:519.</a></li><li class="breakAll">www,fda.gov/medwatch/SAFETY/2005/safety05.htm#Elidel (Accessed on April 15, 2011).</li><li><a class="nounderline abstract_t">Altmeyer P, Kachel HG, Schäfer G, Fassbinder W. [Normalization of uremic skin changes following kidney transplantation]. Hautarzt 1986; 37:217.</a></li></ol></div><div id="topicVersionRevision">Topic 1985 Version 48.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37269433" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Chronic kidney disease-associated pruritus (CKD-aP) is associated with worse quality of life and increased healthcare utilization among dialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37637864" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : The Burden of Pruritus Associated With CKD: A Mixed Methods Analysis Among Patients Undergoing Dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37777951" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Pruritus in Hemodialysis Patients: Longitudinal Associations With Clinical and Patient-Reported Outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17591521" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : An update on pruritus associated with CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7006933" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Pruritus and xerosis in patients with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4010846" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cutaneous abnormalities in uremic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8399656" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Pruritus in continuous ambulatory peritoneal dialysis and hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17586843" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Itchy skin--a clinical problem for haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16672924" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Etiology and prognostic significance of severe uremic pruritus in chronic hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16968725" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pruritus in haemodialysis patients: International results from the Dialysis Outcomes and Practice Patterns Study (DOPPS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10703675" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Naltrexone does not relieve uremic pruritus: results of a randomized, double-blind, placebo-controlled crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33604539" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Self-reported Pruritus and Clinical, Dialysis-Related, and Patient-Reported Outcomes in Hemodialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28923831" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : International Comparisons of Prevalence, Awareness, and Treatment of Pruritus in People on Hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1699691" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Uremic pruritus in patients on hemodialysis or continuous ambulatory peritoneal dialysis (CAPD). The role of plasma histamine and skin mast cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19384842" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The impact of pruritus on the quality of life of patients undergoing dialysis: a single centre cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Ura mischer pruritus im Kindes- und Jugendalter</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27366666" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Comparison of uremic pruritus between patients undergoing hemodialysis and peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26945400" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : A Comparison of Uremic Pruritus in Patients Receiving Peritoneal Dialysis and Hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30975656" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pruritus and Patient Reported Outcomes in Non-Dialysis CKD.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7872318" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Optimal dialysis improves uremic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1436334" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Dialysis efficacy and itching in renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/5670911" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Intractable pruritus as a manifestation of secondary hyperparathyroidism in uremia. Disappearance of itching after subtotal parathyroidectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10625234" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : A study on pruritus after parathyroidectomy for secondary hyperparathyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31384331" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Clinical features and risk factors of pruritus in patients with chronic renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4003393" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Uremic pruritus: skin divalent ion content and response to ultraviolet phototherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16995341" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Uremic pruritus is associated with higher kt/V and serum calcium concentration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Uremic dermatitis</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13877511" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The eccrine sweat glands of patients in uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9031270" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Is aluminum toxicity responsible for uremic pruritus in chronic hemodialysis patients?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19250445" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Clinical implications of disordered magnesium homeostasis in chronic renal failure and dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3135016" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Serological markers of renal itch in patients receiving long term haemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1545849" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Relief of pruritus and decreases in plasma histamine concentrations during erythropoietin therapy in patients with uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6432548" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : UV treatment of uraemic pruritus reduces the vitamin A content of the skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12517579" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Pruritic dermatoses: overview of etiology and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19190625" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Skin problems in chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12198205" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Uraemic pruritus--new perspectives and insights from recent trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16249205" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : The role of micro-inflammation in the pathogenesis of uraemic pruritus in haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7936015" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Thalidomide for the treatment of uremic pruritus: a crossover randomized double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/464448" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Ultraviolet phototherapy of uremic pruritus. Long-term results and possible mechanism of action.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15150348" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : A prospective proof of concept study of the efficacy of tacrolimus ointment on uraemic pruritus (UP) in patients on chronic dialysis therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21372257" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Interleukin-2 serum levels are elevated in patients with uremic pruritus: a novel finding with practical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12454228" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Inflammation and pruritus in haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12606187" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Itch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14512095" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Involvement of central mu-opioid system in the scratching behavior in mice, and the suppression of it by the activation of kappa-opioid system.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16791143" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : The neurobiology of itch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16791143" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The neurobiology of itch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11135647" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Spinothalamic lamina I neurons selectively sensitive to histamine: a central neural pathway for itch.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9629255" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Pain modulatory actions of cytokines and prostaglandin E2 in the brain.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1816135" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Elevated plasma histamine in chronic uremia. Effects of ketotifen on pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16836494" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : An epidemiology study of patients with uremic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4519082" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Dermatologic evaluation of pruritus in patients on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11501646" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : A questionnaire for the assessment of pruritus: validation in uremic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14576662" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Prevalence and characterization of uremic pruritus in patients undergoing hemodialysis: uremic pruritus is still a major problem for patients with end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6938707" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Winter itch, dry skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29253847" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Nalbuphine ER Tablets for Uremic Pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28263039" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Sertraline can reduce uremic pruritus in hemodialysis patient: A double blind randomized clinical trial from Southern Iran.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31702883" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15783121" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Improvement in uremic symptoms after increasing daily dialysate volume in patients on chronic peritoneal dialysis with declining renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23940749" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Uremic pruritus, dialysis adequacy, and metabolic profiles in hemodialysis patients: a prospective 5-year cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18422797" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Uremic pruritus, cytokines, and polymethylmethacrylate artificial kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11453873" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Polymethylmethacrylate efficacy in reduction of renal itching in hemodialysis patients: crossover study and role of tumor necrosis factor-alpha.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17586845" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Uraemic itching: do polymethylmethacrylate dialysis membranes play a role?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19175617" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : A randomized controlled trial of high-permeability haemodialysis against conventional haemodialysis in the treatment of uraemic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8918718" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Pruritus and skin hydration during dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15663539" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Effect of skin care with an emollient containing a high water content on mild uremic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21258039" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Randomized, double-blind study with glycerol and paraffin in uremic xerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18821119" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : A pramoxine-based anti-itch lotion is more effective than a control lotion for the treatment of uremic pruritus in adult hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8730431" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Hemodialysis-related pruritus: a double-blind, placebo-controlled, crossover study of capsaicin 0.025% cream.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1732343" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Topical capsaicin for treatment of hemodialysis-related pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9092738" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Uremic pruritus: roles of parathyroid hormone and substance P.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21128913" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Systematic review of topical capsaicin in the treatment of pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2884733" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : [Pruritus in chronic uremic patients in periodic hemodialysis. Treatment with terfenadine (an antagonist of histamine H1 receptors)].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15575002" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Gabapentin therapy for pruritus in haemodialysis patients: a randomized, placebo-controlled, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17679749" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Gabapentin: a promising drug for the treatment of uremic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15772928" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Gabapentin in the treatment of uremic itch: an index case and a pilot evaluation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27022338" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Comparison of Gabapentin and Ketotifen in Treatment of Uremic Pruritus in Hemodialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27043168" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Gabapentin: A promising therapy for uremic pruritus in hemodialysis patients: A randomized-controlled trial and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22819436" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Use of pregabalin in the management of chronic uremic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20969735" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : The use of pregabalin in the treatment of uraemic pruritus in haemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25099523" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Comparison of pregabalin with ondansetron in treatment of uraemic pruritus in dialysis patients: a prospective, randomized, double-blind study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27397522" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Comparison of pregabalin with doxepin in the management of uremic pruritus: a randomized single blind clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22909343" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Pregabalin versus gabapentin in the treatment of neuropathic pruritus in maintenance haemodialysis patients: a prospective, crossover study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33283264" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Interventions for itch in people with advanced chronic kidney disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35511180" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Efficacy and Safety of Difelikefalin in Japanese Patients With Moderate to Severe Pruritus Receiving Hemodialysis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32405581" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Randomized Controlled Trial of Difelikefalin for Chronic Pruritus in Hemodialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36016762" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Efficacy of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis of KALM-1 and KALM-2 Phase 3 Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Difelikefalin for Hemodialysis Patients with Pruritus in Japan</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36039153" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Safety and Tolerability of Difelikefalin for the Treatment of Moderate to Severe Pruritus in Hemodialysis Patients: Pooled Analysis From the Phase 3 Clinical Trial Program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33982405" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Effect of difelikefalin, a selective kappa opioid receptor agonist, on respiratory depression: A randomized, double-blind, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35991692" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Difelikefalin: A Novel Therapy for Dialysis Patient Care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28270926" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Targeting the Opioid Pathway for Uremic Pruritus: A Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27379625" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Comparison of high-flux hemodialysis with hemodialysis filtration in treatment of uraemic pruritus: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22973512" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Effect of sertraline on uremic pruritus improvement in ESRD patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23777329" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Use of sertraline for antihistamine-refractory uremic pruritus in renal palliative care patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37270517" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : The effectiveness of sertraline in alleviating uremic pruritus in hemodialysis patients: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9585892" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Uremic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15965439" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Treatment of uremic pruritus with narrowband ultraviolet B phototherapy: an open pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28164894" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : A controlled trial of narrowband ultraviolet B phototherapy for the treatment of uremic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37098678" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Vitamin D and narrowband ultraviolet B phototherapy for chronic kidney disease-associated pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11812197" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Ultraviolet B induces mast cell apoptosis: a hypothetical mechanism of ultraviolet B treatment for uraemic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25885112" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Pharmacokinetics of nalbuphine hydrochloride extended release tablets in hemodialysis patients with exploratory effect on pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16488311" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Butorphanol for treatment of intractable pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/389168" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Relief of intractable pruritus with naloxone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6467691" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Naloxone in the treatment of uremic pruritus: a case history.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8950882" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Randomised crossover trial of naltrexone in uraemic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15178915" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : A comparative study on the effects of naltrexone and loratadine on uremic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9933750" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Effects of oral supplementation with evening primrose oil for six weeks on plasma essential fatty acids and uremic skin symptoms in hemodialysis patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35112475" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Pruritus-reducing effects of omega-3 fatty acids in hemodialysis patients: A cross-over randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23115713" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Efficacy of omega-3 fatty acids supplementation in treatment of uremic pruritus in hemodialysis patients: a double-blind randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24482090" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Effects of turmeric on uremic pruritus in end stage renal disease patients: a double-blind randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22458392" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Zinc sulfate for relief of pruritus in patients on maintenance hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36055470" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Acupuncture for Uremic Pruritus: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7436164" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Relief of idiopathic generalized pruritus in dialysis patients treated with activated oral charcoal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7566302" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Oral activated charcoal in patients with uremic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17675729" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Effect of oral granisetron in uremic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16623673" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Cromolyn sodium: a potential therapy for uremic pruritus?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20007756" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Effect of oral cromolyn sodium on CKD-associated pruritus and serum tryptase level: a double-blind placebo-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/322794" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Cholestyramine in uraemic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2708742" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Double-blind, placebo-controlled study of nicergoline in the treatment of pruritus in patients receiving maintenance hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31261951" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Chronic Pruritus Responding to Dupilumab-A Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30993160" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : A successful case of dupilumab treatment for severe uremic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19363280" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Montelukast for treatment of refractory pruritus in patients on hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28174353" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Therapeutic Effect of Montelukast for Treatment of Uremic Pruritus in Hemodialysis Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16797388" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Therapeutic effect of topical gamma-linolenic acid on refractory uremic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23006933" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Sericin cream reduces pruritus in hemodialysis patients: a randomized, double-blind, placebo-controlled experimental study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16324422" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Efficacy and tolerance of the cream containing structured physiological lipids with endocannabinoids in the treatment of uremic pruritus: a preliminary study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25916632" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Effect of topical vitamin D on chronic kidney disease-associated pruritus: An open-label pilot study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22732382" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Efficacy of topical cromolyn sodium 4% on pruritus in uremic nephrogenic patients: a randomized double-blind study in 60 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11216583" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Short-term efficacy of tacrolimus ointment in severe uremic pruritus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15761435" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15761435" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Lack of efficacy of tacrolimus ointment 0.1% for treatment of hemodialysis-related pruritus: a randomized, double-blind, vehicle-controlled study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3516928" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : [Normalization of uremic skin changes following kidney transplantation].</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
